HYFT at a glance
The past year
Chart−46.0% $0.91, close Nov 17
- From the highest close
- −67.4%
- Vs the 200-day average
- −32.3%
Short interest
History1.1M shares
- Since the last report
- +4.3%
- Days to cover
- 6.3 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 12 – Nov 18
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
HYFT price history
Loading recent earnings…
Investment thesis
What must happen next
Biopharma customers must continue seeing MindWalk’s specialized antibody/pharmaceutical capabilities as worth outsourcing, so demand can expand without the company buying growth through price cuts or uneconomic work.HoldingMateriality: High
IFRS annual revenue was CAD24.520m in FY2025, roughly unchanged from CAD24.518m in FY2024, so the customer base did not collapse despite losses. If specialized demand returns, the revenue base can absorb fixed scientific and corporate costs; if customers defect or insource, the business remains subscale.
Watch: Large CROs or discovery vendors such as Charles River, WuXi Biologics, GenScript, Eurofins, or Thermo Fisher win outsourced antibody/discovery work on broader scale, lower price, or bundled offerings.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
IFRS annual revenue was CAD24.520m in FY2025, roughly unchanged from CAD24.518m in FY2024, so the customer base did not collapse.
Open source ↗MindWalk’s offering must remain technically differentiated enough to protect pricing and project mix, rather than drifting into commoditized low-margin discovery services.StrengtheningMateriality: High
IFRS annual gross profit increased to CAD13.548m in FY2025 from CAD12.053m in FY2024 while revenue was essentially flat. Gross margin is the clearest evidence that customers pay for value, not just capacity; losing that would remove the main path to profitable scale.
Watch: Price competition from larger CROs or antibody-discovery providers forces MindWalk to discount to keep utilization.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
IFRS annual gross profit increased to CAD13.548m in FY2025 from CAD12.053m in FY2024 while revenue was essentially flat.
Open source ↗Management must turn the fixed scientific, platform, and corporate cost base into operating leverage; otherwise even attractive gross margins will not create owner value.WeakeningMateriality: Medium
IFRS annual operating cash flow was negative CAD6.410m in FY2025, far better than negative CAD19.833m in FY2023, suggesting cash burn can be managed. This is the difference between a scalable platform and a perpetual cash-burn story.
Watch: Management continues funding broad R&D, AI, platform, or therapeutic ambitions without corresponding commercial partnerships.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
IFRS annual operating cash flow was negative CAD6.410m in FY2025, far better than negative CAD19.833m in FY2023, suggesting cash burn.
Open source ↗The balance sheet must provide enough runway for a commercial or cost-structure inflection, or the next funding step will capture value from shareholders through dilution or restrictive capital.HoldingMateriality: Medium
Cash was CAD10.791m at FY2025 year-end, up from CAD3.545m at FY2024 year-end. For an unprofitable microcap, survival financing can dominate business progress and determine per-share outcomes.
Watch: MindWalk cannot secure non-dilutive partnership, licensing, customer prepayment, grant, or asset-sale funding.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was CAD10.791m at FY2025 year-end, up from CAD3.545m at FY2024 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Biopharma customers must continue seeing MindWalk’s specialized antibody/pharmaceutical capabilities as worth outsourcing, so demand can expand without the company buying growth through price cuts or uneconomic work. If specialized demand returns, the revenue base can absorb fixed scientific and corporate costs; if customers defect or insource, the business remains subscale.
MindWalk’s offering must remain technically differentiated enough to protect pricing and project mix, rather than drifting into commoditized low-margin discovery services. Gross margin is the clearest evidence that customers pay for value, not just capacity; losing that would remove the main path to profitable scale.
Management must turn the fixed scientific, platform, and corporate cost base into operating leverage; otherwise even attractive gross margins will not create owner value. This is the difference between a scalable platform and a perpetual cash-burn story.
The balance sheet must provide enough runway for a commercial or cost-structure inflection, or the next funding step will capture value from shareholders through dilution or restrictive capital. For an unprofitable microcap, survival financing can dominate business progress and determine per-share outcomes.
All standing thesis claims
Original report summary
its former ImmunoPrecise antibody/pharmaceutical platform can prove that specialized discovery demand supports high gross margins while management rightsizes spending fast enough to avoid dilution.
Bull case and bear case
Bull case and bear case for MindWalk Holdings
Where the evidence on MindWalk Holdings disagrees: Mixed on the latest evidence (Nov 9, 2026). Of its 4 thesis points, 1 strengthening, 2 holding and 1 weakening.
Bull case: what the evidence supports
Biopharma customers must continue seeing MindWalk’s specialized antibody/pharmaceutical capabilities as worth outsourcing, so demand can expand without the company buying growth through price cuts or uneconomic work.
MindWalk’s offering must remain technically differentiated enough to protect pricing and project mix, rather than drifting into commoditized low-margin discovery services.
The balance sheet must provide enough runway for a commercial or cost-structure inflection, or the next funding step will capture value from shareholders through dilution or restrictive capital.
Bear case: what the evidence questions
Management must turn the fixed scientific, platform, and corporate cost base into operating leverage; otherwise even attractive gross margins will not create owner value.
Thesis-Break Engine
Thesis-break watch · MindWalk Holdings
No break has crossed MindWalk Holdings’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedForeign issuer material report (6-K).
MindWalk Holdings filed an SEC report on 2026-11-04: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
MindWalk Holdings filed an SEC report on 2026-10-28: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
MindWalk Holdings filed an SEC report on 2026-10-22: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large CROs or discovery vendors such as Charles River, WuXi Biologics, GenScript, Eurofins, or Thermo Fisher win outsourced antibody/discovery work on broader scale, lower price, or bundled offerings.
- Price competition from larger CROs or antibody-discovery providers forces MindWalk to discount to keep utilization.
- Management continues funding broad R&D, AI, platform, or therapeutic ambitions without corresponding commercial partnerships.
- MindWalk cannot secure non-dilutive partnership, licensing, customer prepayment, grant, or asset-sale funding.
HYFT news
Loading headlines…
Financial statements
HYFT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
HYFT: quick answers
- What is HYFT's short interest?
- As of October 30, 2026, 1.1M HYFT shares were sold short, up 4.3% from the count before. At the stock's average daily volume that is 6.3 days to cover. FINRA publishes the count twice a month. HYFT short interest history

